Physician profile
Barbara E Fardo
NPI 1902890270
$13,089.35
in general payments reported to CMS, 2019-2025
63 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $1,361 · 2021: $1,901 · 2022: $1,785 · 2023: $2,315 · 2024: $1,843 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,778 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,777.50 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,745.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,627.18 | 2019-2025 | |
| Pfizer INC. | $1,209.30 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,136.21 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $967.25 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $559.43 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $529.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.85 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $454.88 | 2019-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $408.48 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Abbott Laboratories | $313.15 | 2020-2025 | Proclaim, Freestyle Libre 3 |
| Amarin Pharma, INC. | $303.82 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $259.28 | 2020-2025 | Nexletol, Onzetra Xsail, Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.70 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $244.36 | 2021-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $242.08 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $188.51 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $186.67 | 2023-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $139.13 | 2019-2025 | Injectafer |
| Comsort, INC | $100.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $93.82 | 2024-2025 | Voquezna |
| Allergan, INC. | $92.83 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $85.19 | 2021 | |
| Exact Sciences Corporation | $75.56 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $72.98 | 2021-2025 | |
| Esperion Therapeutics, INC. | $71.34 | 2020-2025 | Nexletol |
| Grifols USA, LLC | $69.50 | 2019 | |
| Sanofi Pasteur INC. | $65.46 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.46 | 2022 | |
| Inari Medical, INC. | $57.34 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ironwood Pharmaceuticals, INC | $51.81 | 2020-2023 | Linzess |
| Shield Therapeutics INC | $51.58 | 2025 | |
| Sumitomo Pharma America, INC. | $49.51 | 2023-2025 | Gemtesa |
| Horizon Therapeutics Plc | $49.31 | 2019-2023 | Krystexxa |
| Tosoh Bioscience, INC. | $47.00 | 2019 | |
| Cequr Corporation | $45.61 | 2022-2023 | Cequr Simplicity |
| Genentech USA, INC. | $43.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $42.75 | 2021-2024 | Zoryve |
| Csl Behring | $40.98 | 2025 | Andembry |
| Teva Pharmaceuticals USA, INC. | $40.33 | 2020-2023 | Airduo Digihaler |
| Vivus LLC | $39.81 | 2019-2021 | |
| Eisai INC. | $38.40 | 2020-2021 | |
| Mylan Specialty L.P. | $35.93 | 2021 | |
| Medicomp INC | $34.42 | 2025 | Telepatch Cardiac Monitor |
| Kaleo, INC. | $30.73 | 2020-2021 | |
| Biogen, INC. | $30.33 | 2021-2023 | Spinraza |
| Melinta Therapeutics, LLC | $29.25 | 2019 | |
| Upsher-Smith Laboratories LLC | $25.37 | 2021 | |
| Axsome Therapeutics, INC. | $24.68 | 2025 | Auvelity |
| Photonicare INC | $23.48 | 2025 | Otosight Middle Ear Scope |
| Vertex Pharmaceuticals Incorporated | $22.70 | 2025 | |
| Organogenesis INC. | $22.33 | 2024 | Puraply Wound Matrix |
| Novartis Pharmaceuticals Corporation | $19.81 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.88 | 2023 | Nuedexta |
| Amneal Pharmaceuticals LLC | $18.74 | 2025 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $17.50 | 2022 | |
| Shire North American Group INC | $17.50 | 2019 | |
| Aytu Biopharma, INC. | $15.57 | 2019 | |
| Verona Pharma, INC. | $14.60 | 2025 | Ohtuvayre |
| Dermira, INC. | $14.39 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.78 | 2024 | Nuzyra |
| Radius Health, INC. | $12.39 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Fardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.